Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Amrita Krishnan(City of Hope), Jesús F. San Miguel(Clinica Universidad de Navarra), María‐Victoria Mateos(Hospital Clínico San Carlos), Niels W.C.J. van de Donk(Oncode Institute), Alfred L. Garfall(University of Pennsylvania), Lionel Karlin(Hôpital Lyon Sud), Manisha Bhutani(Carolinas Healthcare System), Hareth Nahi(Karolinska University Hospital), Ajai Chari(University of California, San Francisco), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Lotfi Benboubker, Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Lixia Pei(Janssen (United States)), Jeffrey R. Infante(Cancer Research Center), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Yusri Elsayed(Janssen (United States)), Albert Oriol(Institut Català d'Oncologia), Laura Rosiñol(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Cited by 321
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k